CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) today reported results for the full year of 2024.

加利福尼亞州卡爾斯巴德，2025年3月24日（全球新聞通訊）——Acutus Medical, Inc.（“Acutus” 或 “公司”）今天公佈了 2024 年全年的業績。

Recent Highlights:

近期亮點：

2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.
Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.
Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.
Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024.

2024 年持續經營收入為 2020 萬美元，同比增長 181%，去年為 720 萬美元。
持續經營的營業虧損為 10 萬美元，而去年為 1170 萬美元。
記錄了 1080 萬美元的業務出售收益，比去年增長 19%。
截至2024年12月31日，現金、現金等價物、可交易證券和受限現金為 1400 萬美元。

Full Year 2024 Financial Results

2024 年全年財務業績

Revenue from Continuing Operations was $20.2 million for 2024, an increase of 181% compared to $7.2 million in 2023.

2024 年持續經營收入為 2020 萬美元，比 2023 年的 720 萬美元增長 181%。

Gross margin on a GAAP basis for continuing operations was 5% for 2024 compared to negative 44% for 2023. The improvement was driven by higher production volumes related to left-heart access manufacturing and reduced manufacturing overhead expenses.

2024 年持續經營的 GAAP 毛利率為 5%，而 2023 年為負 44%。這一改善得益於與左心通道製造相關的生產量增加和製造間接費用的減少。

Operating expenses for continuing operations on a GAAP basis was $1.1 million for 2024 compared to Operating expenses of $8.6 million last year. The decrease in operating expenses from reduced discretionary spend under this new business model.

2024 年持續經營的 GAAP 營業費用為 110 萬美元，而去年為 860 萬美元。營業費用的減少源於在這一新商業模式下減少的可自由支配支出。

Net loss on continuing operations on a GAAP basis was $4.6 million for 2024 and net loss per share was $0.16 on a weighted average basic and diluted outstanding share count of 29.8 million, compared to a net loss of $11.9 million and a net loss per share of $0.4 on a weighted average basic and diluted outstanding share count of 29.1 million for last year.

2024 年持續經營的 GAAP 淨虧損為 460 萬美元，按加權平均基本和稀釋後流通股計，每股淨虧損為 0.16 美元，而去年淨虧損為 1190 萬美元，每股淨虧損為 0.4 美元，按加權平均基本和稀釋後流通股計為 2910 萬股。

Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024.

截至2024年12月31日，現金、現金等價物、可交易證券和受限現金為 1400 萬美元。

Loss on Discontinued Operations

終止經營的虧損

Loss on discontinued operations was $5.0 million for 2024, compared to $69.7 million last year.

2024 年終止經營的虧損為 500 萬美元，而去年為 6970 萬美元。

Outlook

展望

Due to the announced plan to realign resources to support the left-heart access distribution business and exit from the electrophysiology mapping and ablation businesses, the Company will no longer provide financial guidance.

由於宣佈計劃重新調整資源以支持左心通道分銷業務並退出電生理測繪和消融業務，公司將不再提供財務指導。

About Acutus

關於 Acutus

Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.

Acutus 專注於根據與美敦力公司（Medtronic, Inc.）的分銷協議生產左心通道產品。Acutus 成立於 2011 年，總部位於加利福尼亞州卡爾斯巴德。

Caution Regarding Forward-Looking Statements

關於前瞻性聲明的警告

This press release includes statements that may constitute “forward-looking” statements, usually containing the words 'believe", "estimate", "project", "expect" or similar expressions. Forward looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

本新聞稿包含可能構成 “前瞻性” 聲明的內容，通常包含 “相信”、“估計”、“項目”、“期望” 或類似表達。前瞻性聲明固有地涉及風險和不確定性，可能導致實際結果與前瞻性聲明存在重大差異。導致或促成此類差異的因素包括但不限於公司繼續管理費用和現金消耗率的能力、公司重組計劃的成功完成、公司左心通道產品在市場上的持續接受度、全球經濟狀況對美敦力購買公司左心通道產品的能力和意願的影響及其購買時機、競爭因素、美國及全球醫療政策的變化，包括政府對程序的報銷變化、對第三方供應商和分銷商的依賴、監管批准的時機、公司維持在納斯達克上市的能力，以及公司定期和其他向證券交易委員會提交的文件中討論的其他風險。通過發佈這些前瞻性聲明，Acutus 不承擔在本發佈日期後因修訂或變更而更新這些聲明的義務，法律要求的除外。

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com

投資者聯繫：
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com


Acutus Medical, Inc.
Consolidated Balance Sheets

(in thousands, except share and per share amounts)	December 31,2024		December 31,2023
ASSETS
Current assets:
Cash and cash equivalents	$	14,019		$	19,170
Marketable securities, short-term		—			3,233
Restricted cash, short-term		—			7,030
Accounts receivable		7,878			11,353
Inventory		1,790			4,278
Prepaid expenses and other current assets		641			678
Current assets of discontinued operations (Note 3)		1,250			510
Total current assets		25,578			46,252

Property and equipment, net		517			825
Right-of-use assets, net		2,459			3,189
Other assets		94			94
Non-current assets of discontinued operations (Note 3)		—			3,600
Total assets	$	28,648		$	53,960

LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable		1,276			2,761
Accrued liabilities		3,006			2,887
Operating lease liabilities, short-term		957			718
Long-term debt, current portion		7,005			1,864
Warrant liability		194			409
Current liabilities of discontinued operations (Note 3)		—			10,303
Total current liabilities		12,438			18,942

Operating lease liabilities, long-term		2,238			3,243
Long-term debt		25,564			32,654
Total liabilities		40,240			54,839

Commitments and contingencies (Note 12)

Stockholders' (deficit) equity

Preferred stock, $0.001 par value; 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		—			—
Common stock, $0.001 par value; 260,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 29,912,305 and 29,313,667 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		30			29
Additional paid-in capital		598,670			599,935
Accumulated deficit		(609,524	)		(599,977	)
Accumulated other comprehensive loss		(768	)		(866	)
Total stockholders' deficit		(11,592	)		(879	)
Total liabilities and stockholders' deficit	$	28,648		$	53,960


藥明康德， Inc.
合併資產負債表

（以千為單位，除每股和每股金額外）	2024年12月31日		2023年12月31日
資產
流動資產：
現金及現金等價物	$	14,019		$	19,170
短期可交易證券		—			3,233
短期受限現金		—			7,030
應收賬款		7,878			11,353
存貨		1,790			4,278
預付費用及其他流動資產		641			678
停業業務的流動資產（注 3）		1,250			510
流動資產總計		25,578			46,252

淨物業及設備		517			825
淨使用權資產		2,459			3,189
其他資產		94			94
停業業務的非流動資產（注 3）		—			3,600
資產總計	$	28,648		$	53,960

負債及股東（虧損）權益
流動負債：
應付賬款		1,276			2,761
應計負債		3,006			2,887
短期經營租賃負債		957			718
長期債務，當前部分		7,005			1,864
權證負債		194			409
停業業務的流動負債（注 3）		—			10,303
流動負債總計		12,438			18,942

長期經營租賃負債		2,238			3,243
長期債務		25,564			32,654
負債總計		40,240			54,839

承諾和或有事項（注 12）

股東（虧損）權益

優先股，面值$0.001；截至2024年12月31日和2023年12月31日授權 5,000,000 股；截至2024年12月31日和2023年12月31日，已發行並流通的優先股為 6,666 股，指定為 A 系列普通等值優先股		—			—
普通股，面值$0.001；截至2024年12月31日和2023年12月31日授權 260,000,000 股；截至2024年12月31日和2023年12月31日，已發行並流通的普通股為 29,912,305 股和 29,313,667 股		30			29
額外實收資本		598,670			599,935
累計虧損		(609,524	)		(599,977	)
累計其他綜合損失		(768	)		(866	)
股東虧損總計		(11,592	)		(879	)
負債和股東虧損總計	$	28,648		$	53,960


Acutus Medical, Inc.
Consolidated Statements of Operations and Comprehensive Loss

	Year Ended December 31,
(in thousands, except share and per share amounts)	2024		2023
Revenue	$	20,157		$	7,164
Cost of products sold		19,144			10,301
Gross profit (loss)		1,013			(3,137	)

Operating expenses (income):
Research and development		—			3,482
Selling, general and administrative		10,436			14,066
Restructuring		1,448			—
Change in fair value of contingent consideration		—			123
Gain on sale of business		(10,814	)		(9,080	)
Total operating expenses		1,070			8,591
Loss from operations		(57	)		(11,728	)

Other income (expense):
Change in fair value of warrant liability		215			2,937
Interest income		763			2,588
Interest expense		(5,758	)		(5,655	)
Other revenue		301			—
Total other expense, net		(4,479	)		(130	)
Loss from continuing operations before income taxes		(4,536	)		(11,858	)
Income tax (benefit) expense		—			63
Net loss from continuing operations		(4,536	)		(11,921	)
Discontinued operations:
Loss from discontinued operations before income taxes		(4,999	)		(69,530	)
Income tax expense - discontinued operations		12			212
Loss from discontinued operations		(5,011	)		(69,742	)
Net loss	$	(9,547	)	$	(81,663	)

Other comprehensive income (loss):
Unrealized gain on marketable securities		—			7
Foreign currency translation adjustment		98			(4	)
Comprehensive loss	$	(9,449	)	$	(81,660	)

Net loss per share, basic and diluted:
Loss from continuing operations	$	(0.15	)	$	(0.41	)
Loss from discontinued operations	$	(0.17	)	$	(2.40	)
Net loss per common share, basic	$	(0.32	)	$	(2.81	)

Weighted average number of common shares outstanding, basic and diluted		29,768,208			29,095,294


藥明康德， Inc.
合併運營和綜合損失報表

	截至 12 月 31 日的年度
（以千為單位，除每股和每股金額外）	2024		2023
收入	$	20,157		$	7,164
銷售產品成本		19,144			10,301
毛利潤（損失）		1,013			(3,137	)

運營費用（收入）：
研發費用		—			3,482
銷售、一般和行政費用		10,436			14,066
重組費用		1,448			—
有條件對價公允價值變動		—			123
業務出售收益		(10,814	)		(9,080	)
運營費用總計		1,070			8,591
運營損失		(57	)		(11,728	)

其他收入（費用）：
權證負債公允價值變動		215			2,937
利息收入		763			2,588
利息費用		(5,758	)		(5,655	)
其他收入		301			—
其他費用淨額		(4,479	)		(130	)
持續運營的損失（所得税前）		(4,536	)		(11,858	)
所得税（收益）費用		—			63
持續運營的淨損失		(4,536	)		(11,921	)
停業業務：
停業業務的損失（所得税前）		(4,999	)		(69,530	)
停業業務的所得税費用		12			212
停業業務的淨損失		(5,011	)		(69,742	)
淨損失	$	(9,547	)	$	(81,663	)

其他綜合收入（損失）：
短期可交易證券未實現收益		—			7
外幣換算調整		98			(4	)
綜合損失	$	(9,449	)	$	(81,660	)

每股淨損失，基本和稀釋後：
持續運營的損失	$	(0.15	)	$	(0.41	)
停業業務的損失	$	(0.17	)	$	(2.40	)
每普通股淨損失，基本	$	(0.32	)	$	(2.81	)

基本和稀釋後普通股加權平均流通股數		29,768,208			29,095,294


Acutus Medical, Inc.
Consolidated Statements of Cash Flows


(in thousands)	2024		2023
Cash flows from operating activities
Net loss	$	(9,547	)	$	(81,663	)
Less: Loss on discontinued operations		5,011			69,742
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		297			191
Non-cash stock-based compensation expense		459			3,032
Accretion of discounts on marketable securities, net		(28	)		(1,428	)
Amortization of debt issuance costs		931			571
Amortization of operating lease right-of-use assets		730			683
Gain on sale of business, net		(10,814	)		(9,080	)
Change in fair value of warrant liability		(215	)		(2,937	)
Change in fair value of contingent consideration		—			123
Changes in operating assets and liabilities:
Accounts receivable		(4,048	)		(1,074	)
Inventory		2,488			(2,484	)
Employer retention credit receivable		—			4,703
Prepaid expenses and other current assets		48			656
Accounts payable		(1,485	)		288
Accrued liabilities		(246	)		(700	)
Operating lease liabilities		(766	)		(461	)
Other long-term liabilities		—			(12	)
Net cash used in operating activities - continuing operations		(17,185	)		(19,850	)
Net cash used in operating activities - discontinued operations		(14,475	)		(43,268	)
Net cash used in operating activities		(31,660	)		(63,118	)

Cash flows from investing activities
Proceeds from sale of business		18,672			17,000
Purchases of available-for-sale marketable securities		—			(39,765	)
Sales of available-for-sale marketable securities		500			750
Maturities of available-for-sale marketable securities		2,750			82,000
Purchases of property and equipment		(112	)		(219	)
Net cash provided by investing activities - continuing operations		21,810			59,766
Net cash provided by (used in) investing activities - discontinued operations		339			(1,211	)
Net cash provided by investing activities		22,149			58,555

Cash flows from financing activities
Repayment of debt		(2,625	)		—
Payment of debt issuance costs		—			(490	)
Proceeds from the exercise of stock options		—			4
Proceeds from employee stock purchase plan		—			25
Payment of contingent consideration		—			(1,923	)
Net cash used in financing activities - continuing operations		(2,850	)		(2,384	)
Net cash used in financing activities - discontinued operations		(41	)		(280	)
Net cash used in financing activities		(2,891	)		(2,664	)

Effect of exchange rate changes on cash, cash equivalents and restricted cash		221			2,079

Net change in cash, cash equivalents and restricted cash		(12,181	)		(5,148	)
Cash, cash equivalents and restricted cash, at the beginning of the period		26,200			31,348
Cash, cash equivalents and restricted cash, at the end of the period	$	14,019		$	26,200

Supplemental disclosure of cash flow information:
Cash paid for interest	$	4,544		$	5,012

Supplemental disclosure of noncash investing and financing activities:
Changes between assets and liabilities in discontinued operations	$	—		$	5,445
Accounts receivable from sale of business	$	1,838		$	9,360
Change in unrealized (gain) loss on marketable securities	$	—		$	(7	)


Acutus Medical, Inc.
合併現金流量表


(單位：千美元)	2024		2023
來自經營活動的現金流
淨虧損	$	(9,547	)	$	(81,663	)
減：終止經營損失		5,011			69,742
調整淨虧損以對賬用於經營活動的淨現金：
折舊費用		297			191
非現金股票補償費用		459			3,032
可交易證券折扣的增值，淨額		(28	)		(1,428	)
債務發行成本的攤銷		931			571
租賃使用權資產的攤銷		730			683
業務出售收益，淨額		(10,814	)		(9,080	)
權證負債公允價值變動		(215	)		(2,937	)
有條件對價公允價值變動		—			123
經營資產和負債的變動：
應收賬款		(4,048	)		(1,074	)
存貨		2,488			(2,484	)
僱主保留税收抵免應收款		—			4,703
預付費用及其他流動資產		48			656
應付賬款		(1,485	)		288
應計負債		(246	)		(700	)
租賃負債		(766	)		(461	)
其他長期負債		—			(12	)
來自經營活動的淨現金 - 持續經營		(17,185	)		(19,850	)
來自經營活動的淨現金 - 終止經營		(14,475	)		(43,268	)
來自經營活動的淨現金		(31,660	)		(63,118	)

來自投資活動的現金流
業務出售收益		18,672			17,000
購買可供出售的可交易證券		—			(39,765	)
出售可供出售的可交易證券		500			750
可供出售的可交易證券到期		2,750			82,000
購買物業和設備		(112	)		(219	)
來自投資活動的淨現金 - 持續經營		21,810			59,766
來自投資活動的淨現金（使用）- 終止經營		339			(1,211	)
來自投資活動的淨現金		22,149			58,555

來自融資活動的現金流
償還債務		(2,625	)		—
支付債務發行成本		—			(490	)
行使股票期權的收益		—			4
員工股票購買計劃的收益		—			25
支付有條件對價		—			(1,923	)
來自融資活動的淨現金 - 持續經營		(2,850	)		(2,384	)
來自融資活動的淨現金 - 終止經營		(41	)		(280	)
來自融資活動的淨現金		(2,891	)		(2,664	)

匯率變動對現金、現金等價物和受限現金的影響		221			2,079

現金、現金等價物和受限現金的淨變動		(12,181	)		(5,148	)
期初現金、現金等價物和受限現金		26,200			31,348
期末現金、現金等價物和受限現金	$	14,019		$	26,200

現金流信息的補充披露：
支付的利息	$	4,544		$	5,012

非現金投資和融資活動的補充披露：
終止經營中資產與負債的變動	$	—		$	5,445
業務出售的應收賬款	$	1,838		$	9,360
可交易證券未實現（收益）損失的變動	$	—		$	(7	)

Acutus Medical 公佈 2024 年全年財務業績